Hanmi Pharmaceutical, Sanofi deal

Hanmi granted Sanofi exclusive, worldwide rights to develop and commercialize Hanmi’s Quantum Project portfolio of long-acting compounds to treat diabetes. Hanmi received EUR400 million ($440.6 million) up front and is eligible for up to EUR3.5 billion ($3.9 billion) in milestones related to the three programs in the project. Hanmi is also is eligible for double-digit royalties and retains the option to co-commercialize the treatments in China and Korea. ...